ULCERS - Electrical Stimulation in Diabetic Foot Ulceration
Primary Purpose
Diabetes
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
GEKO device
Best Medical Therapy
Sponsored by
About this trial
This is an interventional treatment trial for Diabetes focused on measuring Diabetic Foot, Ulcer healing, Medical device to increase blood flow in foot
Eligibility Criteria
Inclusion criteria
- 18+ years old
- Type 2 diabetes on best medical therapy
- Active foot ulceration, present <3 months Exclusion criteria
- Pregnancy
- Pacemaker
- Metal implants in the legs (below knee)
Sites / Locations
- Diabetic Foot Clinic, Praed Street, Paddington
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
No device
Device
Arm Description
Treated with best medical therapy
As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.
Outcomes
Primary Outcome Measures
Number of Day Until 50% Healing of Leg Ulcer
Time to 50% healing of leg ulcer, as measured by volume (3D camera)
Secondary Outcome Measures
Quality of Life (PAID, EQ5D, VAS, SF-12)
Improvement in quality of life questionnaire values, comparing baseline to 6 weeks with treatment PAID ("Problem Areas in Diabetes") - score 0-80, 0 is no problem, 80 is serious problem EQ5D (standardised instrument for generic quality of life score, https://en.wikipedia.org/wiki/EQ-5D) - combination of different dimensions of health to form an overall index, 1.0 for a perfect state of health, with 0 on the scale representing the state of being dead VAS ("visual analogue scale") - For pain intensity, the scale is anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 100) SF 12 ("short form 12") - weighted and summed to provide easily interpretable scales for physical and mental health, the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health
Full Information
NCT ID
NCT02211495
First Posted
August 5, 2014
Last Updated
November 3, 2020
Sponsor
Imperial College London
1. Study Identification
Unique Protocol Identification Number
NCT02211495
Brief Title
ULCERS - Electrical Stimulation in Diabetic Foot Ulceration
Official Title
Electrical Stimulation in Diabetic Foot Ulceration
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
July 2014 (Actual)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College London
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The investigators hypothesise that use of a medical device, that increases blood flow to the foot, will speed up ulcer healing in symptomatic diabetes
Detailed Description
Diabetes affects approximately 347 million people worldwide, and by 2030 the WHO projects that diabetes will be the 7th leading cause of death. Diabetic foot ulcers are estimated to occur in 15% of all patients with diabetes, often co-existing with neuropathy and peripheral vascular disease which compromise the limb's ability to heal. Foot infections in this cohort are common, and diabetic foot ulcers serve as a portal for infective organisms to enter the body. Unchecked, infection can spread contiguously to involve underlying tissues, including bone. A diabetic foot infection is often the pivotal event leading to gangrene and lower extremity amputation. Diabetes accounts for over one million leg amputations every year, and represents 60% of all amputations in developed countries.
Due to the potential for rapid progression of infection, and the gravity of potential complications, diabetic foot problems are handled aggressively in the community, with a low threshold for referral to secondary care. Out-patient clinics involve a multidisciplinary team of clinicians, podiatrists and vascular surgeons. Good foot care is taught to all diabetic patients, and treatment with antibiotics, debridement and revascularisation should occur as a matter of urgency where appropriate.
The device to be tested mimics the effect of walking by making the foot twitch- it increases blood flow to the limb and exercises the leg muscles. It is hypothesised that increasing blood flow to the limb, much as surgical revascularisation, will aid the legs ability to heal and fight infection. After training, it can be used by patients on themselves and is suitable for out-patient therapy.
The investigators wish to evaluate both the short- and longer-term effects of a neuromuscular stimulator on diabetic foot ulceration as a therapeutic intervention.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes
Keywords
Diabetic Foot, Ulcer healing, Medical device to increase blood flow in foot
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
8 (Actual)
8. Arms, Groups, and Interventions
Arm Title
No device
Arm Type
Active Comparator
Arm Description
Treated with best medical therapy
Arm Title
Device
Arm Type
Experimental
Arm Description
As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.
Intervention Type
Device
Intervention Name(s)
GEKO device
Intervention Description
Placed on the lateral aspect of the knee, when activated it causes the leg to twitch
Intervention Type
Other
Intervention Name(s)
Best Medical Therapy
Intervention Description
Seen in outpatient clinic for wound care and ongoing advice
Primary Outcome Measure Information:
Title
Number of Day Until 50% Healing of Leg Ulcer
Description
Time to 50% healing of leg ulcer, as measured by volume (3D camera)
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Quality of Life (PAID, EQ5D, VAS, SF-12)
Description
Improvement in quality of life questionnaire values, comparing baseline to 6 weeks with treatment PAID ("Problem Areas in Diabetes") - score 0-80, 0 is no problem, 80 is serious problem EQ5D (standardised instrument for generic quality of life score, https://en.wikipedia.org/wiki/EQ-5D) - combination of different dimensions of health to form an overall index, 1.0 for a perfect state of health, with 0 on the scale representing the state of being dead VAS ("visual analogue scale") - For pain intensity, the scale is anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 100) SF 12 ("short form 12") - weighted and summed to provide easily interpretable scales for physical and mental health, the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria
18+ years old
Type 2 diabetes on best medical therapy
Active foot ulceration, present <3 months Exclusion criteria
Pregnancy
Pacemaker
Metal implants in the legs (below knee)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kate Williams
Organizational Affiliation
Imperial College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Diabetic Foot Clinic, Praed Street, Paddington
City
London
ZIP/Postal Code
W2 1NY
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
ULCERS - Electrical Stimulation in Diabetic Foot Ulceration
We'll reach out to this number within 24 hrs